Published in Liver Transpl on November 01, 2006
The multiple universes of estrogen-related receptor α and γ in metabolic control and related diseases. Acta Pharmacol Sin (2014) 0.91
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence. J Transplant (2014) 0.86
Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One (2011) 0.83
A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma. Am J Cancer Res (2015) 0.81
Everolimus and mTOR inhibitors in liver transplantation: opening the "box". Liver Transpl (2006) 0.80
Recurrent hepatitis C after liver transplant. World J Gastroenterol (2014) 0.79
The role of everolimus in liver transplantation. Clin Exp Gastroenterol (2014) 0.79
A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC Surg (2010) 0.78
Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant (2014) 0.76
Multiple indications for everolimus after liver transplantation in current clinical practice. World J Transplant (2014) 0.75
Use of Everolimus in Liver Transplantation: Recommendations From a Working Group. Transplantation (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA (2007) 14.54
Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int (2008) 4.16
Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology (2009) 4.03
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet (2003) 3.89
Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology (2009) 3.57
Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol (2004) 3.56
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology (2008) 3.52
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46
Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 3.43
Architecture of the RNA polymerase II-TFIIF complex revealed by cross-linking and mass spectrometry. EMBO J (2010) 3.40
Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med (2012) 3.27
The protein composition of mitotic chromosomes determined using multiclassifier combinatorial proteomics. Cell (2010) 3.26
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Metal-organic framework materials as catalysts. Chem Soc Rev (2009) 2.96
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology (2003) 2.71
Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl (2014) 2.71
Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg (2007) 2.67
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts. Biom J (2006) 2.61
Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl (2010) 2.57
Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35
Senescence rates are determined by ranking on the fast-slow life-history continuum. Ecol Lett (2008) 2.30
Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell (2013) 2.28
2003 report of the intestine transplant registry: a new era has dawned. Ann Surg (2005) 2.27
Adjuvant therapy in pancreatic cancer: a critical appraisal. Drugs (2007) 2.26
Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. Hepatology (2011) 2.25
Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2004) 2.23
Biliary reconstruction using a side-to-side choledochocholedochostomy with or without T-tube in deceased donor liver transplantation: a prospective randomized trial. Ann Surg (2009) 2.19
Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy? Ann Surg (2012) 2.18
Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol (2012) 2.15
Liver allocation and distribution: possible next steps. Liver Transpl (2011) 2.14
Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology (2014) 2.14
Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl (2006) 2.13
Pulmonary complications after elective liver transplantation-incidence, risk factors, and outcome. Transplantation (2012) 2.11
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling. Am J Transplant (2004) 2.09
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results. Liver Transpl (2007) 2.08
Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation--a randomized, double-blind trial. Am J Transplant (2005) 2.08
The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C. Hepatology (2011) 2.08
Different cava reconstruction techniques in liver transplantation: piggyback versus cava resection. Hepatobiliary Pancreat Dis Int (2014) 2.08
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Prediction of postoperative outcome after hepatectomy with a new bedside test for maximal liver function capacity. Ann Surg (2009) 2.06
Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transpl (2006) 2.04
Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg (2003) 2.02
Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl (2003) 2.01
Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol (2011) 1.99
Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept. Transpl Int (2010) 1.99
3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet (2006) 1.97
A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry. J Hepatol (2011) 1.94
Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl (2011) 1.92
Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg (2007) 1.90
Intrahepatic biliary cystadenoma: role of cyst fluid analysis and surgical management in the laparoscopic era. Surgery (2004) 1.89
The surgical treatment of bilateral benign nodular goiter: balancing invasiveness with complications. Dtsch Arztebl Int (2014) 1.88
Challenges in implementing CD4 testing in resource-limited settings. Cytometry B Clin Cytom (2008) 1.88
Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 1.86
Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology (2010) 1.85
Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA (2010) 1.84
Renal histopathological lesions after orthotopic liver transplantation (OLT). Am J Transplant (2005) 1.79
Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int (2009) 1.77
Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl (2007) 1.76
Hepatic artery thrombosis after adult liver transplantation. Liver Transpl (2003) 1.74
Hospital accused of experiments on pregnant women. BMJ (1994) 1.73
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J Hepatol (2006) 1.72
First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol (2002) 1.71
Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol (2008) 1.70
Mangafodipir prevents liver injury induced by acetaminophen in the mouse. J Hepatol (2003) 1.67
Trends and experiences in liver retransplantation over 15 years. Liver Transpl (2007) 1.66
Living donor liver transplantation: effect of the type of liver graft donation on donor mortality and morbidity. Transpl Int (2010) 1.64
Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study. Liver Transpl (2007) 1.64
Transplantation procedures in children with primary hyperoxaluria type 1: outcome and longitudinal growth. Transplantation (2009) 1.63
US researchers fail to get informed consent. BMJ (1994) 1.61
Open intraperitoneal versus retromuscular mesh repair for umbilical hernias less than 3 cm diameter. Am J Surg (2010) 1.60
Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. J Hepatol (2010) 1.60
Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease. Hepatology (2003) 1.59
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients. World J Gastroenterol (2006) 1.58
Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res (2009) 1.58
Diagnosis and treatment of arterial steal syndromes in liver transplant recipients. Liver Transpl (2003) 1.58
Laparoscopic liver surgery: Shifting the management of liver tumors. Hepatology (2006) 1.58
Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation (2002) 1.57
Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57
Sex is a major determinant of CYP3A4 expression in human liver. Hepatology (2003) 1.57
Extracorporeal liver perfusion as hepatic assist in acute liver failure: a review of world experience. Xenotransplantation (2002) 1.57
Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients. Hepatology (2012) 1.56
Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl (2010) 1.56